Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07191483 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
A Phase 2 study of Cognitive Impairment Associated With Schizophrenia (CIAS), sponsored by Kynexis B.V..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 13
- Study locations
NCT07191483: Recruiting Phase 2 study of Cognitive Impairment Associated With Schizophrenia (CIAS), sponsored by Kynexis B.V..
NCT07191483 is a Phase 2 study of Cognitive Impairment Associated With Schizophrenia (CIAS) that is actively recruiting participants, run by Kynexis B.V.. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07191483, a Phase 2 study of Cognitive Impairment Associated With Schizophrenia (CIAS), is actively recruiting participants, sponsored by Kynexis B.V..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.
Primary Outcome
Change from Baseline at Day 28 in the digital version of the Brief Assessment of Cognition for Schizophrenia (BAC App) composite T-score
Conditions Studied
Interventions
- OTHER Placebo
- DRUG KYN-5356 low dose
- DRUG KYN-5356 Medium Dose
- DRUG KYN-5356 High Dose
Study Locations (13)
California
- Synergy Research Center - Lemon Grove
- Cenexel CNS - Los Alamitos
Florida
- Cenexel RCA - Hollywood
- Segal Trials - Miami Lakes
Georgia
- Cenexel ACMR - Atlanta
- Cenexel iResearch Atlanta - Decatur
Arkansas
- Woodland International Research Group - Little Rock
Illinois
- Uptown Research Institute - Chicago
Maryland
- Cenexel CBH - Gaithersburg
Missouri
- Arch Clinical Trials - St Louis
New Jersey
- Cenexel HRI - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT07191483 shows while recruiting
NCT07191483 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Cognitive Impairment Associated With Schizophrenia (CIAS) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07191483 lists 13 locations in 10 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT07191483 about?
NCT07191483 is a clinical study titled "A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia". This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN...
What is the current status of trial NCT07191483?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-08-27. Estimated completion is 2026-12.
What conditions does trial NCT07191483 study?
This clinical trial studies the following conditions: Cognitive Impairment Associated With Schizophrenia (CIAS).
What interventions are being tested in trial NCT07191483?
The interventions under investigation include: Placebo (OTHER), KYN-5356 low dose (DRUG), KYN-5356 Medium Dose (DRUG), KYN-5356 High Dose (DRUG).
Who is sponsoring clinical trial NCT07191483?
This trial is sponsored by Kynexis B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07191483 being conducted?
This trial has 13 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07191483's enrollment target sits among peer trials
150 455th of 2000 higher than 1,511 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI